ArticleScientific reports2021

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.

Yuko Kusakabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.